Notch signaling in normal and disease States: possible therapies related to glycosylation.
The Notch signaling pathway is involved in a wide variety of highly conserved developmental processes in mammals. Importantly, mutations of the Notch protein and components of its signaling pathway have been implicated in an array of human diseases (T-cell leukemia and other cancers, Multiple Sclerosis, CADASIL, Alagille Syndrome, Spondylocostal Dysostosis). In mammals, Notch becomes activated upon binding of its extracellular domain to ligands (Delta and Jagged/Serrate) that are present on the surface of apposed cells. The extracellular domain of Notch contains up to 36 tandem Epidermal Growth Factor-like (EGF) repeats. Many of these EGF repeats are modified at evolutionarily-conserved consensus sites by an unusual form of O-glycosylation called O-fucose. Work from several groups indicates that O-fucosylation plays an important role in ligand mediated Notch signaling. Recent evidence also suggests that the enzyme responsible for addition of O-fucose to Notch, protein O-fucosyltransferase-1 (POFUT1), may serve a quality control function in the endoplasmic reticulum. Additionally, some of the O-fucose moieties are further elongated by the action of members of the Fringe family of beta-1,3-N-acetylglucosaminyltransferases. The alteration in O-fucose saccharide structure caused by Fringe modulates the response of Notch to its ligands. Thus, glycosylation serves an important role in regulating Notch activity. This review focuses on the role of glycosylation in the normal functioning of the Notch pathway. As well, potential roles for glycosylation in Notch-related human diseases, and possible roles for therapeutic targeting of POFUT1 and Fringe in Notch-related human diseases, are discussed.
Rampal
Raajit
R
Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, Stony Brook University, Stony Brook, New York, 11794-5215, USA.
Luther
Kelvin B
KB
Haltiwanger
Robert S
RS
D016738:Alagille Syndrome / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D046589:CADASIL / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000201:enzymology / Q000473:pathology; D005643:Fucose / Q000235:genetics / Q000378:metabolism; D005647:Fucosyltransferases / Q000235:genetics / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins; D000072100:Jagged-1 Protein; D015458:Leukemia, T-Cell / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D009103:Multiple Sclerosis / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D017351:N-Acetylglucosaminyltransferases / Q000235:genetics / Q000378:metabolism*; D046188:Protein Modification, Translational; D017434:Protein Structure, Tertiary / Q000235:genetics; D051880:Receptors, Notch / Q000235:genetics / Q000378:metabolism*; D000072099:Serrate-Jagged Proteins; D015398:Signal Transduction / Q000235:genetics
D002135:Calcium-Binding Proteins; D036341:Intercellular Signaling Peptides and Proteins; D047908:Intracellular Signaling Peptides and Proteins; C000606273:JAG1 protein, human; D000072100:Jagged-1 Protein; D008565:Membrane Proteins; D051880:Receptors, Notch; D000072099:Serrate-Jagged Proteins; C064045:delta protein; D005643:Fucose; D005647:Fucosyltransferases; D017351:N-Acetylglucosaminyltransferases